Glatiramer Acetate Injection, Solution
Product Images NDC 47335-991

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 47335-991). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Glatirtamer Actetate Injection (Glatiramer Acetate 40 mg Per mL 1)

A Kaplan-Meier survival curve comparing Glatiramer Acetate injection with placebo over time. The x-axis represents days, ranging from 0 to over 1000 days, while the y-axis shows cumulative incidence percentage up to 60%. Two lines indicate patient groups: one for Glatiramer Acetate injection and one for placebo, showing a lower cumulative incidence for the treatment group. Statistical values p=0.0005 and hazard ratio=0.55 are noted.*

FDA Label Image

Figure G (Glatiramer Acetate 40 mg Per mL 10)

An instructional illustration showing a person administering a subcutaneous injection using a syringe on the upper thigh. The person uses one hand to pinch the skin and the other hand to insert the needle at an angle, demonstrating proper injection technique.*

FDA Label Image

Figure H (Glatiramer Acetate 40 mg Per mL 11)

An instructional illustration showing a person administering a subcutaneous injection, holding a syringe and injecting into the skin on the thigh area. The image emphasizes proper hand positioning and injection technique.*

FDA Label Image

Figure I (Glatiramer Acetate 40 mg Per mL 12)

An instructional illustration showing a pair of hands administering a subcutaneous injection using a syringe, with one hand holding the syringe and the other pinching the skin to prepare the injection site.*

FDA Label Image

Figure J (Glatiramer Acetate 40 mg Per mL 13)

An instructional illustration showing a hand holding a syringe to administer a subcutaneous injection into an arm. The image demonstrates the proper angle and technique for injecting the solution under the skin.*

FDA Label Image

Figure K (Glatiramer Acetate 40 mg Per mL 14)

An instructional illustration showing a person performing a subcutaneous injection on the thigh. The image demonstrates the hand holding two fingers of the opposite hand to pinch the skin, preparing the injection site for Glatiramer Acetate 40 mg/mL injection solution.*

FDA Label Image

Figure L (Glatiramer Acetate 40 mg Per mL 15)

Illustration of a medical sharps disposal container with a biohazard symbol on the front, used for safely discarding needles and other sharp medical instruments.*

FDA Label Image

Logo Sun Pharma (Glatiramer Acetate 40 mg Per mL 16)

FDA Label Image

Glatiramer Acetate Injection 40 mg/ml (Box)

Label for Glatiramer Acetate Injection 40 mg/mL by Sun Pharmaceutical Industries, Inc., indicating it contains 12 single-dose pre-filled syringes for subcutaneous injection, dosed three times a week. The label includes the NDC 47335-991-02 and notes the prescription status (Rx only).*

FDA Label Image

Figure 2 Glatiramer Acetate Injection (Glatiramer Acetate 40 mg Per mL 2)

A line graph comparing the median cumulative number of enhancing lesions over 9 months between two groups: one receiving Glatiramer acetate injection and the other receiving placebo. The horizontal axis represents time in months, and the vertical axis shows the number of lesions. The Glatiramer acetate group shows a slower increase in lesions compared to the placebo group, indicated by separate lines.*

FDA Label Image

Logo Sun Pharma (Glatiramer Acetate 40 mg Per mL 3)

FDA Label Image

Figure A (Glatiramer Acetate 40 mg Per mL 4)

An instructional diagram displaying items related to subcutaneous injection administration. It includes a sharps disposal container, two cotton balls, alcohol wipes packets, a syringe enclosed in blister packaging, and an injection diary notebook. These items are labeled accordingly in the illustration.*

FDA Label Image

Figure B (Glatiramer Acetate 40 mg Per mL 5)

An instructional illustration showing two hands preparing an injection. One hand holds a rectangular box while the other hand removes a syringe from inside the box. This likely depicts the preparation step for subcutaneous injection of Glatiramer Acetate, 40 mg/mL solution by Sun Pharmaceutical Industries.*

FDA Label Image

Figure C (Glatiramer Acetate 40 mg Per mL 6)

Illustrations showing recommended subcutaneous injection sites for Glatiramer Acetate injection solution, 40 mg/mL. Areas include the abdomen (avoiding 2 inches around the belly button), fleshy parts of upper hips and arms below the waist, upper back portion of arms, and thighs approximately 2 inches above the knee and 2 inches below the groin.*

FDA Label Image

Figure D (Glatiramer Acetate 40 mg Per mL 7)

An instructional illustration showing a person applying a small adhesive patch or bandage to the upper thigh area, suggesting proper site care for an injection.*

FDA Label Image

Figure E (Glatiramer Acetate 40 mg Per mL 8)

An instructional illustration showing a hand holding a syringe, demonstrating steps to prepare an injection. The sequence includes removing a cap from the syringe, holding the syringe ready for use, and finally the syringe with the needle exposed, with the cap placed aside. This visual is relevant for subcutaneous injection preparation.*

FDA Label Image

Figure F (Glatiramer Acetate 40 mg Per mL 9)

An instructional illustration showing a hand pinching the skin on the upper arm, likely demonstrating the technique for subcutaneous injection administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.